Genomic data from a pharmacogenetic study based on the efficacy of Tocilizumab in severe COVID-19 patients

These data correspond to a pharmacogenetic study aimed to explore genetic associations related to the efficacy of Tocilizumab in severe COVID-19 patients. The study comprised two sets of patients, an initial subset consisted of 425 patients to whom a in-dpeth sequencing of a thermofisher sequencing panel of immune-related genes was performed, as well as a second set of 245 patients with the information of the genotyping of three selected SNPs